Hims & Hers Insiders Sell $47 Million — Three of Four Exit to Zero Shares

Three of four recently filing insiders at Hims & Hers Health (HIMS) have sold down to zero shares, generating a combined $47.4 million in career stock sales. The telehealth company — which has attracted attention for its compounded GLP-1 weight loss offerings — is seeing a broad insider exodus.

COO Leads the Dollar Volume

Chief Operating Officer Michael Chi has generated the largest proceeds at $35.5 million across 262 transactions. Unlike his colleagues, Chi still holds shares — but the volume of selling (262 transactions) suggests systematic, ongoing liquidation. His most recent $1.4 million in sales continues the pattern.

Three Complete Exits

Insider	Title	Career Sales	Transactions	Shares After
Michael Chi	Chief Operating Officer	$35.5M	262	Reduced
Patrick Harrison Carroll	Chief Medical Officer	$6.5M	137	0
Irene Becklund	Principal Accounting Officer	$4.6M	279	0
Deborah M. Autor	Chief Policy Officer	$0.8M	29	0

The CMO Walks Away

Chief Medical Officer Patrick Harrison Carroll sold $6.5 million across 137 transactions before exiting completely with $4.9 million in recent sales. For the top medical executive at a health-focused telehealth company to hold zero shares is particularly notable — Carroll is the person ultimately responsible for Hims & Hers' clinical approach and product safety.

279 Transactions, Zero Shares

PAO Irene Becklund filed an extraordinary 279 transactions generating $4.6 million, with her final $1.7 million in recent sales bringing her to zero. Chief Policy Officer Deborah M. Autor — the executive navigating Hims & Hers through its regulatory challenges — sold $0.8 million across 29 transactions, also exiting completely.

The GLP-1 Question

Hims & Hers has become one of the most debated stocks in the market. The company's entry into compounded semaglutide (the active ingredient in Ozempic/Wegovy) attracted millions of customers — but the FDA's recent moves against compounded GLP-1 drugs have created significant regulatory uncertainty.

When the Chief Medical Officer, the Chief Policy Officer (who handles regulatory strategy), and the Principal Accounting Officer all sell to zero shares, the signal goes beyond routine diversification. These are the executives closest to the regulatory and financial reality of the business.

Monitor all Hims & Hers insider activity on the HIMS stock page.